Group 6C: HER2-low Breast Cancer; Sequencing Antibody-drug Conjugates

Poster #PS08-04: Multicenter retrospective cohort study of the sequential use of the Antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC).

Poster #PS08-03: Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): Multi-institution experience and biomarker analysis.